VNRX Stock Forecast: VolitionRX Ltd. Price Predictions for 2026-2027
The median 12-month analyst price target for VolitionRX Ltd. is $20. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 53 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores VolitionRX Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (84): Analysts have, on balance, been raising their forecasts.
Value (19): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
VNRX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VNRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Apr 2026 | D. Boral Capital | Downgrade | Hold | — |
| 2 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 26 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 18 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 21 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 9 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 18 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 3 Dec 2025 | Maxim Group | Downgrade | Hold | — |
| 26 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Nov 2025 | Freedom Broker | Maintains | Buy | — |
| 17 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 17 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 17 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 9 July 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VNRX.
This page is one stock. Monday covers all of them.
VNRX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
VNRX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, VolitionRX Ltd. returned −97.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
VNRX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.7×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 53% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −161.9%
- Dividend yield
- —
Higher than 1% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
VolitionRX Ltd. has a market value of $5.8M and an enterprise value of $10.2M.
Revenue in the twelve months to 30 June 2026: $2.5M. The latest quarter shrank 2.0% year on year.
Net income over the same four quarters: −$25.7M, a −1046.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$19.6M.
VolitionRX Ltd. employs 54 people — $46K of revenue per employee.
Data provided by Twelve Data
VNRX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at VNRX’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own VolitionRX Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about VNRX
What is the VNRX stock price forecast for 2026-2027?
The median 12-month analyst price target for VolitionRX Ltd. is $20, with estimates ranging from $2.11 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is VNRX stock a buy right now?
Of the 5 analysts covering VolitionRX Ltd., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks VolitionRX Ltd. 53 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank VNRX?
As at 21 Nov 2026, VolitionRX Ltd. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (84 of 100).
Will VNRX stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $20, and Ticker Nerd's factor model ranks VolitionRX Ltd. 53 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the VNRX stock forecast for 2030?
No analyst covering VolitionRX Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VNRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.11 to $24 over the next 12 months.
How has VNRX stock performed over the past year?
VolitionRX Ltd. returned -97.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does VolitionRX Ltd. do?
VolitionRx Limited is a multi-national epigenetics company focused on developing blood-based diagnostic tests for human and animal health. Its current product portfolio centers on the Nu.Q platform, which uses nucleosome-based biomarkers to help detect, monitor, and assess cancers and diseases associated with NETosis, including sepsis.
About VolitionRX Ltd.
VolitionRx Limited is a multi-national epigenetics company focused on developing blood-based diagnostic tests for human and animal health. Its current product portfolio centers on the Nu.Q platform, which uses nucleosome-based biomarkers to help detect, monitor, and assess cancers and diseases associated with NETosis, including sepsis. The company also offers veterinary applications such as Nu.Q Vet and research tools such as Nu.Q Discover, alongside technologies designed to support earlier disease detection and treatment monitoring. VolitionRx Limited serves healthcare and life sciences markets across the United States, Europe, and Asia from its headquarters in Henderson, Nevada.
CEO Mr. Cameron Reynolds MBA · 54 employees · United States · https://volition.com